Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 13,160 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Urogenital Diseases Clear all
Completed Phase 2 Interventional Results available

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

NCT00677092
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis
Interventions
Imatinib mesylate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

NCT03369236
View directory record Official record
Conditions
C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
17 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 10, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

NCT06686537
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Estradiol Patches
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 10, 2026, 5:35 AM EDT
Not yet recruiting Not applicable Interventional

The Goal is to Examine the Impact of Doula-coordinated, Midwife-delivered Postpartum Care Among Individuals With Preterm Births <34 Weeks' Gestation Requiring NICU Admission.

NCT07787845
View directory record Official record
Conditions
Doula Support, Postpartum, Postpartum Anaemia, Postpartum Depression (PPD)
Interventions
Doula-coordinated, Midwife-delivered postpartum care
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Early Phase 1 Interventional

Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer

NCT03028519
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Vitamin D3
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 10, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

NCT03562507
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic
Interventions
ESK981, Nivolumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 10, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

NCT05928936
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium Bicarbonate, Exercise Training, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
40 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 10, 2026, 5:35 AM EDT
Active, not recruiting Phase 3 Interventional

Preeclampsia Postpartum Antihypertensive Treatment

NCT04298034
View directory record Official record
Conditions
Preeclampsia, Hypertension in Pregnancy
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 10, 2026, 5:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Determination of Voiding Patterns of Children With Vesicoureteral Reflux

NCT00186199
View directory record Official record
Conditions
Vesicoureteral Reflux
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 16 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing KIM to TVT Exact Sling

NCT04985799
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Gynecare TVT Exact Continence System, Neomedic KIM (Knotless Incontinence Mesh)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Hillsborough, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Not applicable Interventional

PRevention of Acute Kidney Injury Initiated With Electronic Surveillance Enhancement

NCT01621152
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Conventional management arm, AKI sniffer instigated AKI management
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Modern Urodynamics System Efficacy (MUSE) Study

NCT05959655
View directory record Official record
Conditions
Urologic Diseases, Urodynamics
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Murrieta, California • Newport Beach, California • East Setauket, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Not applicable Interventional

A Peer-Led Intervention to Improve Postpartum Retention in HIV Care

NCT04168008
View directory record Official record
Conditions
HIV/AIDS
Interventions
WISH Adherence, WISH Parenting
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

NCT00026091
View directory record Official record
Conditions
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
Interventions
fenretinide, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 10, 2026, 5:35 AM EDT
Withdrawn Early Phase 1 Interventional

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

NCT00713921
View directory record Official record
Conditions
Urinary Incontinence, Bladder Dysfunction
Interventions
Fesoterodine Oral Product
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
21 Years to 85 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 10, 2026, 5:35 AM EDT
Active, not recruiting No phase listed Observational

Kidney Function in Sickle Cell Anemia

NCT03277547
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Failure, Chronic
Interventions
Not listed
Lead sponsor
Kenneth Ataga MD
Other
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Columbus, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

NCT00664326
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 10, 2026, 5:35 AM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 10, 2026, 5:35 AM EDT
Active, not recruiting Phase 1 Interventional

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

NCT02496208
View directory record Official record
Conditions
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 5:35 AM EDT
Withdrawn Phase 4 Interventional

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

NCT03093740
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
Zepatier, Zepatier plus Sofosbuvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 10, 2026, 5:35 AM EDT
Withdrawn Phase 4 Interventional

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

NCT03623568
View directory record Official record
Conditions
Kidney Failure, Kidney Diseases, Hepatitis C
Interventions
glecaprevir/pibrentasvir tablets
Drug
Lead sponsor
Raymond T. Chung, MD
Other
Eligibility
30 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 10, 2026, 5:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

NCT07064018
View directory record Official record
Conditions
Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions
Spedox-6, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

NCT02146313
View directory record Official record
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms
Interventions
DMUC4064A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Sarasota, Florida • Boston, Massachusetts • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 10, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

NCT03345485
View directory record Official record
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 10, 2026, 5:35 AM EDT